A PHASE 1 STUDY OF A THIRD-GENERATION ONCOLYTIC HSV-1 G47Δ IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER

被引：1
|
作者：
Fukuhara, Hiroshi
Takeshima, Yuta
Homma, Yukio
Ino, Yasushi
Todo, Tomoki
机构：
来源：
JOURNAL OF UROLOGY | 2016年 / 195卷 / 04期
关键词：
D O I：
10.1016/j.juro.2016.02.399
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD28-12
引用
收藏
页码：E658 / E659
页数：2
相关论文
共 50 条
  • [41] Editorial Comment on: A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer
    van der Poel, Henk G.
    EUROPEAN UROLOGY, 2009, 56 (01) : 103 - 104
  • [42] Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine
    Lim, Emerson A.
    Petrylak, Daniel P.
    Peng, Weimin
    Kheoh, Thian
    Maul, Scott
    Smit, Johan W.
    Gonzalez, Martha D.
    De Porre, Peter
    NamPhuong Tran
    Nanus, David M.
    EUROPEAN UROLOGY, 2016, 70 (05) : 718 - 721
  • [43] A Randomized Phase 1 Study of Testosterone Replacement for Patients With Low-Risk Castration-Resistant Prostate Cancer Editorial Comment
    Walsh, Patrick C.
    JOURNAL OF UROLOGY, 2009, 182 (06): : 2729 - 2730
  • [44] Docetaxel and curcuminoids combination in patients with castration-resistant prostate cancer: A phase II study
    Mahammedi, H.
    Pouget, M.
    Planchat, E.
    Cure, H.
    Durando, X.
    Van-Praagh, I.
    Savareux, L.
    Abrial, C.
    Chollet, P.
    Eymard, J. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S696
  • [45] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
    Guadalupi, V.
    Giganti, M. O.
    Testa, I.
    Villa, S.
    Nicolai, N.
    Biasoni, D.
    Salvioni, R.
    Valdagni, R.
    Bajetta, E.
    Procopio, G.
    ANTICANCER RESEARCH, 2010, 30 (04) : 1536 - 1536
  • [46] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS (CRPC)
    Verzoni, E.
    Bajetta, E.
    Giganti, M. O.
    Guadalupi, V.
    Capone, F.
    Donegani, S.
    Nicolai, N.
    Salvioni, R.
    Valdagni, R.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 278 - 278
  • [47] Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer
    Laber, Damian A.
    Chen, Min-Bin
    Jaglal, Michael
    Patel, Ankita
    Visweshwar, Nathan
    CLINICAL GENITOURINARY CANCER, 2018, 16 (06) : 473 - 481
  • [48] Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
    Michaelson, M. D.
    Bellmunt, J.
    Hudes, G. R.
    Goel, S.
    Lee, R. J.
    Kantoff, P. W.
    Stein, C. A.
    Lardelli, P.
    Pardos, I.
    Kahatt, C.
    Nieto, A.
    Cullell-Young, M.
    Lewis, N. L.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1234 - 1240
  • [49] Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer
    Morris, Michael J.
    Huang, Daisy
    Kelly, William K.
    Slovin, Susan F.
    Stephenson, Ryan D.
    Eicher, Caitlin
    Delacruz, Anthony
    Curley, Tracy
    Schwartz, Lawrence H.
    Scher, Howard I.
    EUROPEAN UROLOGY, 2009, 56 (02) : 237 - 244
  • [50] Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
    Nobuaki Matsubara
    Hirofumi Mukai
    Ako Hosono
    Mai Onomura
    Masaoki Sasaki
    Yoko Yajima
    Kensei Hashizume
    Masanobu Yasuda
    Miho Uemura
    Christian Zurth
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1073 - 1077
12345